Genix Pharmaceuticals Corporation
GENX.V
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -166.93% | 288.00% | 5.21% | -44.85% | 98.43% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -99.80% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | -- | -- |
| Total Other Non-Cash Items | 120.28% | -790.42% | -0.83% | 112.28% | -99.56% |
| Change in Net Operating Assets | -112.07% | 954.55% | 152.38% | -800.00% | -95.42% |
| Cash from Operations | -50.00% | 11.64% | 22.27% | -36.83% | 29.37% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 31.73% | -10.73% | -20.61% | 46.02% | -36.09% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 26.56% | -10.29% | -21.48% | 45.30% | -40.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -744.44% | 80.00% | 150.00% | 111.76% | -131.48% |